Abeona therapeutics® announces fda acceptance of bla resubmission of pz-cel for the treatment of recessive dystrophic epidermolysis bullosa

Cleveland, nov. 12, 2024 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today announced that the u.s. food and drug administration (fda) has accepted for review abeona's resubmission of its biologics license application (bla) for prademagene zamikeracel (pz-cel), its investigational autologous cell-based gene therapy, as a potential new treatment for recessive dystrophic epidermolysis bullosa (rdeb). the fda has assigned a prescription drug user fee act (pdufa) target action date of april 29, 2025.
ABEO Ratings Summary
ABEO Quant Ranking